Is Cagrilintide safe?
Emerging ResearchSide effects, risks, and safety considerations based on available research.
Research status
Cagrilintide has some clinical data but research is still developing. Safety data exists but may come from small studies, short-term trials, or specific populations that may not reflect your situation.
Known concerns & side effects
- ⚠CagriSema is not yet FDA or EMA approved — currently accessible only through clinical trials or off-label compounding
- ⚠GI side effects (nausea, vomiting, diarrhea) are consistent with the semaglutide component and were common during dose escalation
- ⚠weight regain upon discontinuation is expected — as with all GLP-1 class drugs, CagriSema likely requires long-term use to maintain results
- ⚠cagrilintide monotherapy has less efficacy data than the combination — the bulk of the evidence is for CagriSema together
- ⚠calcitonin receptor agonism raises theoretical bone metabolism questions with long-term use — under active investigation
- ⚠cost, access, and insurance coverage will be major factors upon approval
- ⚠long-term cardiovascular outcome data for CagriSema is not yet available
Use caution with
Relevant safety research
Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1)
Finding: Mean body weight reduction of 20.4% with CagriSema vs 3.0% with placebo at week 68. 60% of participants achieved ≥20% weight loss; 23% achieved ≥30%. Significant improvements in blood pressure, waist circumference, lipids, and cardiometabolic markers. 88% of participants with prediabetes at baseline returned to normoglycemia.
Limitation: Excluded patients with type 2 diabetes. Novo Nordisk-sponsored. GI side effects were common and led to some discontinuations. Trial product estimand (idealized adherence) vs. treatment policy estimand showed different point estimates.
See all 2 studies on the full Cagrilintide profile.
Frequently asked questions
What is CagriSema and is it available?
CagriSema is a fixed-dose combination of cagrilintide 2.4mg and semaglutide 2.4mg in a single once-weekly injection, developed by Novo Nordisk. As of May 2026, it is not yet FDA or EMA approved. Novo Nordisk filed for FDA approval in late 2025, with review expected in 2026. It is not currently available as a standard prescription.
How does cagrilintide differ from semaglutide?
They target different receptor systems. Semaglutide is a GLP-1 receptor agonist. Cagrilintide is a dual amylin and calcitonin receptor agonist. Amylin regulates appetite through a different brain pathway than GLP-1, and the two signals appear to have complementary rather than redundant mechanisms — explaining why the combination produces greater weight loss than either drug alone.
Is 20% weight loss really possible with CagriSema?
Yes — the REDEFINE 1 trial published in the NEJM (June 2025) showed a mean body weight reduction of 20.4% vs 3.0% placebo at week 68, with 60% of participants achieving ≥20% and 23% achieving ≥30%. These are the largest weight reductions ever reported in a randomized trial of an obesity medication, placing CagriSema above tirzepatide and retatrutide on this metric.
How does CagriSema compare to tirzepatide and retatrutide?
By mean weight loss in phase 3 trials: retatrutide (early phase 2 data) showed ~24%, CagriSema ~20.4%, tirzepatide ~22.5% at highest dose, semaglutide ~15%. These trials used different populations and durations, so direct comparisons require caution. CagriSema is the only one targeting the amylin pathway — a mechanistically distinct approach from the GIP/GLP-1 class.
Full Cagrilintide Profile
Evidence, timeline, products & more
Take the Peptide Quiz
Get personalized recommendations
Last updated: 2026-05-13
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.